Indicated for the treatment of adult patients with:
Multiple myeloma (MM), in combination with dexamethasone
MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)
Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities
Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib
Previously treated follicular lymphoma (FL), in combination with a rituximab product
Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product
